Antibiotics for community acquired pneumonia in adult outpatients

Bjerre, Lise M.; Verheij, Theo; Kochen, Michael M.

doi:10.1002/14651858.cd002109.pub3

Cited by 25 publications

(18 citation statements)

References 83 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[14] The overall conclusions of the review remain the same. Categorisation of antibiotics in outpatient settings (compared with no antibiotics) unchanged (Likely to be beneficial).…”

Section: Benefits and Harmsmentioning

confidence: 85%

“…49/229 (21%) with clarithromycin 476 people with community-acquired pneumonia [14] Systematic review 113/247 (46%) with erythromycin 2 RCTs in this analysis Most adverse effects were gastrointestinal…”

Section: Drug-related Adverse Effectsmentioning

confidence: 94%

“…[14] Systematic review Randomisation method was unclear in both RCTs, and allocation concealment was unclear in 1 RCT 117/124 (94%) with erythromycin…”

Section: Clinical Curementioning

confidence: 99%

“…501 people with community-acquired pneumonia Data from 1 RCT [14] Systematic review 62/252 (25%) with extended-release clarithromycin (1 g/day for 7 days) Most adverse effects were gastrointestinal --…”

Section: Clinical Curementioning

confidence: 99%

“…Further information on studies [14] The systematic review (search date 2009, 6 RCTs) compared different antibiotic treatments for community-acquired pneumonia in ambulatory outpatients over 12 years of age. The systematic review had stringent inclusion and exclusion criteria, and excluded studies if inpatient and outpatient results were not reported separately.…”

Section: Clinical Curementioning

confidence: 99%

See 4 more Smart Citations

Community‐Acquired Pneumonia

Johnson¹,

Irving²,

Jd³

2008

View full text Add to dashboard Cite

INTRODUCTION: In the northern hemisphere about 12/1000 people a year (on average) contract pneumonia while living in the community, with most cases caused by Streptococcus pneumoniae. Mortality ranges from about 5% to 35% depending on severity of disease, with a worse prognosis in older people, men, and people with chronic diseases. METHODS AND OUTCOMES: We conducted a systematic review and aimed to answer the following clinical questions: What are the effects of interventions to prevent community-acquired pneumonia? What are the effects of treatments for community-acquired pneumonia in outpatient settings, in people admitted to hospital, and in people receiving intensive care? We searched: Medline, Embase, The Cochrane Library, and other important databases up to January 2010 (Clinical Evidence reviews are updated periodically; please check our website for the most up-to-date version of this review). We included harms alerts from relevant organisations such as the US Food and Drug Administration (FDA) and the UK Medicines and Healthcare products Regulatory Agency (MHRA). RESULTS: We found 15 systematic reviews, RCTs, or observational studies that met our inclusion criteria. We performed a GRADE evaluation of the quality of evidence for interventions. CONCLUSIONS: In this systematic review we present information relating to the effectiveness and safety of the following interventions: antibiotics (oral, intravenous), different combinations, and prompt administration of antibiotics in intensive-care settings, early mobilisation, influenza vaccine, and pneumococcal vaccine.

show abstract

“…[14] The overall conclusions of the review remain the same. Categorisation of antibiotics in outpatient settings (compared with no antibiotics) unchanged (Likely to be beneficial).…”

Section: Benefits and Harmsmentioning

confidence: 85%

Section: Drug-related Adverse Effectsmentioning

confidence: 94%

“…[14] Systematic review Randomisation method was unclear in both RCTs, and allocation concealment was unclear in 1 RCT 117/124 (94%) with erythromycin…”

Section: Clinical Curementioning

confidence: 99%

Section: Clinical Curementioning

confidence: 99%

Section: Clinical Curementioning

confidence: 99%

See 3 more Smart Citations

Community‐Acquired Pneumonia

Johnson¹,

Irving²,

Jd³

2008

View full text Add to dashboard Cite

show abstract

Antibiotics for community-acquired pneumonia in adult outpatients

Pakhalé

Mulpuru

Verheij

et al. 2014

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

BackgroundLower respiratory tract infection (LRTI) is the third leading cause of death worldwide and the first leading cause of death in low-income countries. Community-acquired pneumonia (CAP) is a common condition that causes a significant disease burden for the community, particularly in children younger than five years, the elderly and immunocompromised people. Antibiotics are the standard treatment for CAP. However, increasing antibiotic use is associated with the development of bacterial resistance and side e ects for the patient. Several studies have been published regarding optimal antibiotic treatment for CAP but many of these data address treatments in hospitalised patients. This is an update of our 2009 Cochrane Review and addresses antibiotic therapies for CAP in outpatient settings. ObjectivesTo compare the e icacy and safety of di erent antibiotic treatments for CAP in participants older than 12 years treated in outpatient settings with respect to clinical, radiological and bacteriological outcomes.

show abstract